

In the Claims:

~~Please cancel claims 1-29 and 33-38 without prejudice to later prosecution.~~

a<sup>2</sup>  
30. (Amended) [The] An immunoadhesin [of claim 29, further] comprising a polypeptide comprising an amino acid sequence of the EGF-like domain of SEQ ID NO:4, wherein the polypeptide binds to ErbB4 receptor and activates receptor tyrosine phosphorylation of the ErbB4 receptor.

31. (Amended) The immunoadhesin of claim [29] 30 wherein the immunoglobulin sequence is an immunoglobulin heavy chain constant domain sequence. 112 2nd

32. (Reiterated) The immunoadhesin of claim 31 wherein the immunoglobulin sequence is a constant domain sequence of an IgG-1, IgG-2 or IgG-3.

Please add the following new claims:

--39. The polypeptide of claim 30 encoded by a NRG3 nucleic acid open reading frame sequence in ATCC deposit 209156 (pLXSN.mNRG3). SEQ ID NO = 1 mouse, page 10, 91-92

40. The polypeptide of claim 30 encoded by a NRG3 nucleic acid open reading frame sequence in ATCC deposit 209157 (pRK5.tk.neo.hNRG3B1). SEQ ID NO = 5, human, page 10, 91-92

a<sup>3</sup>  
41. The polypeptide of claim 30 encoded by a NRG3 nucleic acid open reading frame sequence in ATCC deposit 209155 (pRK5.tk.neo.hNRG3B2). ? SEQ ID NO = 22  
209297

42. The polypeptide of claim 30 which is devoid of a cytoplasmic domain, or devoid of a transmembrane domain that can anchor the polypeptide in a cell membrane, or both.

43. The polypeptide of claim 30 unaccompanied by native glycosylation.

New matter

112 2nd